Aethlon Medical Discloses Notice of Allowance for Broad-Spectrum Virus Patent.

SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application (10/760,810) entitled, "Method for Removal of Viruses from Blood by Lectin Affinity Hemodialysis." The claims underlying the patent reinforce the proprietary nature of the Aethlon Hemopurifier([R]) as a potential treatment for a broad-spectrum of infectious disease targets. The patent includes thirteen claims associated with the immobilization of lectins around porous hollow-fiber membranes as a method to remove viruses and toxic viral particles from blood. Lectins are carbohydrate-binding proteins recently discovered to bind a wide range of infectious viruses. Aethlon disclosed that all claims have been allowed, and expects the patent to issue within three to four months after payment of the USPTO issuance fee.

"This patent is a strategic component of our growing intellectual property portfolio," stated Aethlon Chairman and CEO, James A. Joyce. "The timing for protecting our methods to remove a broad-spectrum of circulating viruses could not be better as legislation now mandates support for broad-spectrum treatments against bioterror and pandemic threats," concluded Mr. Joyce.

Aethlon Medical believes its Hemopurifier([R]) treatment technology is a leading broad-spectrum treatment candidate. The Hemopurifier([R]) is designed to assist in the treatment of multiple bioterror threats, including Smallpox, Ebola, Marburg, Lassa fever, and potentially genetically engineered viruses purposely developed to defeat traditional drug and vaccine therapy. The shift towards broad-spectrum countermeasures able to combat multiple viral threats is documented within the new Department of Health and Human Services (HHS) Public Health Emergency Medical Countermeasures Enterprise Strategy (HHS PHEMCE Strategy) which outlines goals and objectives that HHS will employ to ensure that medical countermeasures are available for high priority bioterror and pandemic threats. The preeminent focus of previous legislation was fixed defenses attempting to align a specific treatment with each known bioterror and pandemic threat. The changes implemented under the HHS PHEMCE Strategy were posted in the Federal Register on March 20, 2007.

About Aethlon Medical

Aethlon Medical has developed a first-in-class medical device to assist in the treatment of infectious disease. The device, known as the Hemopurifier[R], is a platform technology positioned to be a broad-spectrum treatment for drug and vaccine resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). On March 6, 2007, Aethlon submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) requesting permission to initiate human safety studies of the Aethlon Hemopurifier([R]) as a treatment countermeasure against select category "A" bioterror threats. Additional studies to demonstrate utility of the Hemopurifier([R]) as a countermeasure against bioterror threats are being conducted with researchers at The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Category "A" bioterror threats are defined by the CDC as agents that pose a risk to national security; are easily disseminated or transmitted from person to person; result in high mortality rates; may cause public panic and social disruption, and require special action for public health preparedness. Global researcher Frost & Sullivan awarded the Hemopurifier([R]) the 2006 Technology Innovation Award, and The AIDS Institute presented Aethlon with the 2007 Innovative HIV Life Sciences Leadership Award. The Company has also initiated research on a second generation Hemopurifier([R]) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.